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Background: The hepatocyte growth factor (HGF)/c-Met pathway 
is often dysregulated in non–small-cell lung cancer (NSCLC). HGF 
activation of c-Met induces cyclooxygenase-2 (COX-2), resulting in 
downstream stimulation by prostaglandin E2 of additional pathways. 
Targeting both c-Met and COX-2 might lead to enhanced antitumor 
effects by blocking signaling upstream and downstream of c-Met.
Methods: Effects of crizotinib or celecoxib alone or in combination 
were tested in NSCLC cells in vitro and in mice transgenic for airway 
expression of human HGF.
Results: Proliferation and invasion of NSCLC cells treated with a 
combination of crizotinib and celecoxib were significantly lower 
compared with single treatments. Transgenic mice showed enhanced 
COX-2 expression localized to preneoplastic areas following expo-
sure to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone, which was not present without carcinogen exposure. 
This shows that COX-2 activity is present during lung tumor devel-
opment in a high HGF environment. After 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone treatment, a significant decrease in the 
number of lung tumors per animal was observed after 13-week 
treatments of crizotinib, celecoxib, or the combination compared 
with placebo (p < 0.001). With combination treatment, the number 
of tumors was also significantly lower than single agent treatment 
(p < 0.001). In the resulting lung tumors, P-c-Met, COX-2, pros-
taglandin E2, and P-MAPK were significantly downmodulated by 
combination treatment compared with single treatment. Expression 
of the epithelial-mesenchymal transition markers E-cadherin and 
snail was also modulated by combination treatment.
Conclusions: In the presence of high HGF, dual inhibition of c-Met 
and COX-2 may enhance antitumor effects. This combination may 
have clinical potential in NSCLCs with high HGF/c-Met expression 
or epithelial-mesenchymal transition phenotype.
Key Words: HGF, COX-2, c-Met, Lung cancer, Crizotinib, Celecoxib.
(J Thorac Oncol. 2014;9: 1285–1293)
Targeted therapies are increasingly being used in the treat-ment of lung cancer, and this approach is most beneficial in 
patients with dysregulation of the specific pathway being inhib-
ited.1,2 In the case of inhibitors of the c-Met pathway, clinical 
benefit has been seen in non–small-cell lung cancer (NSCLC) 
patients with either dysregulated c-Met expression (through 
gene amplification or overexpression)3 or dysregulated ligand 
production (increased hepatocyte growth factor [HGF] expres-
sion).4 We recently showed that increased HGF serum levels are 
very common in patients with lung cancer,5 and increased HGF 
serum level was found by us and others to be a biomarker for 
the presence of lung cancer.5–7 We also have reported increased 
susceptibility to development of lung cancer in a transgenic 
mouse that overexpresses HGF in the airways.8 This increased 
tumorigenic effect in response to a tobacco carcinogen can be 
overcome by use of a neutralizing antibody to HGF.8
One of the downstream effects of c-Met signaling in 
response to HGF is induction of cyclooxygenase-2 (COX-2),9–12 
the inducible rate-limiting enzyme responsible for the production 
of prostaglandin E2 (PGE2). PGE2 mediates protumor effects 
through paracrine stimulation of inflammatory cells and through 
autocrine stimulation of its receptors on tumor cells.13,14 One of 
the important protumor effects of PGE2 in NSCLC is repression 
of E-cadherin expression,13 leading to stimulation of epithelial-
mesenchymal transition (EMT), a key mechanism that promotes 
invasion and tumor progression.15 We found in NSCLC cells that 
COX-2 was often induced after HGF treatment, with subsequent 
heightened release of PGE2.9 PGE2 in turn caused release of 
ligands for the EGFR pathway that led to the activation of EGFR 
signaling along with a delayed activation of c-Met that was not 
dependent on HGF.9 Further mechanistic studies in our labora-
tory showed that functional c-Met was needed for maximal inva-
sion in response to EGFR activation, which was not blocked by 
an HGF neutralizing antibody,16 showing that c-Met activation 
through lateral signals from other tyrosine kinase receptors, inde-
pendent of HGF, contributes to the protumor effects of c-Met.
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In this report, we tested the relevance of our published 
mechanistic data on lateral signaling to determine whether 
enhanced antitumor effects could be achieved by blocking 
the activation of c-Met by HGF using a c-Met small molecule 
tyrosine kinase inhibitor (TKI), along with blockade of c-Met 
downstream reinforcing signaling that is initiated by PGE2 
using a COX-2 inhibitor. Effects of dual inhibition were first 
evaluated in cell culture using NSCLC cell lines and then were 
validated in an animal model with increased HGF expression 
in the airways that also shows evidence of increased COX-2 
activity in response to carcinogen treatment. Dual treatment 
with the c-Met small molecule TKI crizotinib and the COX-2 
inhibitor celecoxib resulted in greater antitumor effects in 
both systems. In the animal model, evidence of reduced down-
stream c-Met signaling was found and biomarkers associated 
with EMT were also maximally inhibited by combination 
treatment. This combination has potential clinical benefit for 
lung cancer patients with dysregulated HGF/c-Met pathways 
and/or evidence of an EMT phenotype.
MATERIALS AND METHODS
Reagents and Cell Culture
NSCLC cell lines 201T and 273T were established in our 
laboratory from primary tissue and maintained at 37°C in 5% 
CO
2.
17 All cells were grown in Basal Medium Eagle (Invitrogen 
Life Technologies, Inc., Grand Island, NY) with 10% fetal bovine 
serum and 2 mM L-glutamine. All cell lines were validated by 
genotyping within 2 months of conducting the experiments. 
Crizotinib was purchased from ChemieTek (Indianapolis, IN). 
Celecoxib in capsule form was obtained from the University of 
Pittsburgh Cancer Institute Pharmacy. Celecoxib was dissolved 
in dimethyl sulfoxide, and the molarity of the stock solution 
was adjusted based on the pharmaceutical formulation. HGF 
was purchased from R&D Systems (Minneapolis, MN).
Cell Proliferation Assay
NSCLC cells were plated in 96-well plates at 1 × 104 
cells/well and grown in Basal Medium Eagle supplemented 
with 10% fetal bovine serum. Experimental treatments were 
added as indicated in the figure legend. Cell proliferation was 
monitored after 72 hours using the CellTiter 96 Aqueous One 
Solution Cell Proliferation Assay Kit (Promega Corporation, 
Madison, WI). Metabolically active cells were labeled with 
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) (MTS) tetrazolium for 2 
hours and measured at 490 nM using an absorbance plate reader 
(Bio-Rad Laboratories, Hercules, CA). The data were analyzed 
by Prism4 (GraphPad Software, La Jolla, CA) to determine the 
concentration that inhibits 25% (IC
25
) and concentration that 
inhibits 50% (IC
50
) concentrations of each inhibitor.
Matrigel Invasion Assay
Invasion assays were conducted using 24-well Matrigel-
coated transwell chambers (BD Biosciences, San Jose, CA). 
NSCLC cells (1 × 105) were plated in full serum in the upper 
chamber. Both the upper and the lower chambers contained 
drug treatment. Noninvading cells in the upper chamber were 
removed after 24 hours by cotton swab, and invading cells 
were fixed and stained using the Diff-Quik staining solu-
tion kit, according to the manufacturer’s instructions (VWR 
International, Radnor, PA). The number of invading cells was 
counted at ×10 magnification. Invaded cell number was nor-
malized to cell proliferation at the same time point for each 
treatment. The mean ± SE was calculated from three indepen-
dent experiments.
Protein Extraction and Western Analysis
Lung cancer cells were grown to 85% confluency in T75 
flasks. Protein extraction, quantitation, and Western analysis 
were performed, as described previously.9
Murine Tumorigenesis Model
All mice used for the experiments were human HGF 
transgenic (FVB/N strain; HGF TG), permissive in the air-
ways under control of the Clara cell secretory protein (CCSP) 
promoter, and heterozygous for the transgene with high copy 
number as described previously.8 These mice show enhanced 
lung tumorigenesis compared with their wild-type litter-
mates and express three to four times the amount of HGF in 
the airways compared with wild-type littermates.8 Breeding 
and identification of transgenic mice were as described pre-
viously.8 Mice were given a total of eight intraperitoneal 
injections of 3 mg 4-(methylnitrosamino)-1-(3-pyridyl)-1-bu-
tanone (NNK; 15μg/μl) over 4 weeks. Celecoxib (50 mg/kg), 
crizotinib (40 mg/kg), or the combination was administered 
five times per week by oral gavage from week 3 until week 
15. At the end of week 15, animals were killed and lungs were 
formalin inflated. Dose of crizotinib was based on our pre-
viously published results in reducing lung carcinogenesis.5 
Celecoxib dose was based on our prior observations in lung 
cancer xenograft studies (data not shown); the dose used falls 
in the low-dose range according to other models.18 We did not 
observe any systemic toxicity of either the NNK treatments 
or the therapeutic treatments. Mice did not show weight loss, 
hair loss, bruising, or general toxicity during these experi-
ments. Tumors on the surface of the lungs were counted under 
a dissecting microscope, and tumor size (defined as surface 
area, mm2) was measured using Motic Images 2000 software 
(Motic). Animal care was in strict compliance with the insti-
tutional guidelines established at the University of Pittsburgh. 
This protocol was approved by the University of Pittsburgh 
IACUC committee (Protocol Number 12057507).
Immunohistochemistry
Mouse lungs were fixed in 10% buffered formalin. Lung 
samples were paraffin embedded, sliced, and mounted on 
slides. Slides were stained with the following antibodies: PGE2 
(1:750; Ab2318; Abcam, Cambridge, MA), COX-2 (1:100; 
160107; Cayman Chemical, Ann Arbor, MI), P-MAPK (1:400; 
4370; Cell Signaling Technology), E-cadherin (1:500; 160107; 
Cayman Chemical), Snail (1:500; Ab53519; Abcam), and P-c-
Met (1:200; 3077; Cell Signaling Technology). All antibodies 
react with mouse antigens. Quantitation for COX-2, PGE2, 
P-MAPK, and P-c-Met was performed in three to five tumors 
per treatment group on a 1 to 4 scaling system: 1 = 1% to 25% 
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positive stained cells, 2 = 26% to 50% positive stained cells, 3 = 
51% to 75% positive stained cells, and 4 = 76% to 100% positive 
stained cells. All positive cells were scored, including epithelial 
cells and immune cells. Immune cells were determined by histo-
logical examination of morphological characteristics by a certi-
fied pathologist of a serial H&E section from the same sample. 
The number of positive cells was counted for E-cadherin and 
snail (scale bar = 50 or 100 μM depending on figure).
Statistical Analysis
For in vitro studies, analysis of variance was used. Effect 
of in vitro drug combinations was tested for synergy using the 
method by Chou and Talalay.19 In the mouse model, Poisson 
regression was used to compare the mean number of tumors 
per mouse in each treatment group, and linear contrasts were 
used to determine which groups differed significantly from one 
another. To examine the differences in tumor sizes between 
treatment groups, we used a linear mixed effects regression 
model. For immunohistochemical quantitation, analysis of 
variance was used. All statistical tests were two-sided, with 
the threshold for statistical significance defined as p < 0.05. 
Analyses were conducted with SAS v. 9.2 (Cary, NC).
RESULTS
Antitumor Effects of Combined 
Crizotinib and Celecoxib
Because COX-2 action is downstream of c-Met signal-
ing induced by HGF and upstream of HGF-independent lat-
eral signaling to c-Met in NSCLC,9 we examined whether the 
combination of inhibiting the c-Met pathway with crizotinib 
and the COX-2 pathway with celecoxib would have enhanced 
antiproliferative effects in NSCLC. We first tested the combi-
nation in cell culture. The IC
25
 and IC
50
 of each inhibitor was 
first determined in two NSCLC cell lines with normal c-Met 
copy number: 201T cells that show high c-Met expression and 
low COX-2 basal expression,9 and 273T cells that show low 
c-Met expression and high COX-2 basal expression (Fig. 1A, 
inset).9 Both cell lines show induction of COX-2 above basal 
levels upon treatment with HGF.9 The IC
25
 for crizotinib was 
4.3 μM in 201T cells and 2.5 μM in 273T cells; the IC
50
 
for crizotinib was 7.8 and 4.6 μM in 201T and 273T cells, 
respectively. For celecoxib, the IC
25
 and IC
50
 were 23.6 and 
48.6 μM in 201T cells and 38.6 and 80.5 μM in 273T cells. 
The effect of combining each inhibitor at its IC
25
 or IC
50
 con-
centration (determined from prior concentration-response 
curves) was examined. At either the IC
25
 or the IC
50
 concentra-
tion, increased antiproliferation effects were observed for the 
combination that were statistically significant compared with 
single agent treatment. Figure 1A shows proliferation results 
at the IC
50
 concentrations of celecoxib and crizotinib. In both 
201T and 273T cells, the combination resulted in 18% to 22% 
relative cell proliferation compared with control, whereas cell 
proliferation relative to control was 43% to 50%, as expected 
with each drug alone at its calculated IC
50
. Supplemental 
Figure 1 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A613) shows proliferation results at the IC
25
 con-
centration of each drug. A statistical test for synergy was 
negative and showed that the effects of the combination on 
proliferation were additive. Similar results were observed in 
an additional NSCLC cell line, H23 (data not shown).
Because c-Met and PGE2 are key mediators of invasion, 
a phenotype that is driven largely by the EMT process,13,20,21 
we also examined the effect of the combination of celecoxib 
and crizotinib on invasion in 201T and 273T cells, using the 
same concentrations of celecoxib and crizotinib as shown 
for Figure 1A. As seen in Figure 1B, the number of cells that 
invaded through the Matrigel matrix in 24 hours was signifi-
cantly decreased by 40% with celecoxib alone and by 44% 
with crizotinib alone in each cell line, whereas combination 
treatment decreased the number of invading cells by 73% 
in 201T cells (p < 0.01 compared with celecoxib alone and 
p < 0.05 compared with crizotinib alone). In 273T cells, the 
combination decreased the number of invading cells by 60% 
(p < 0.05 compared with celecoxib alone and NS compared 
with crizotinib alone). 273T cells showed a higher degree of 
variation in the extent of invasion in replicates compared with 
201T cells. The invasion phenotype showed additive (but not 
synergistic) effects with the drug combination as observed for 
the proliferation end point.
COX-2 Is Observed in Preneoplasias Formed 
after NNK Treatment in HGF Transgenic Mice
We then sought to demonstrate the benefit of dual crizo-
tinib/celecoxib treatment in an animal model of enhanced 
pulmonary HGF activity using an HGF TG mouse with 
transgene expression controlled by the CCSP,8 modeling the 
increased levels of HGF that we have observed in many lung 
cancer patients.5 HGF TG mice express three to four times 
the amount of HGF in bronchoalveolar lavage fluid compared 
with wild-type littermates and show enhanced c-Met path-
way activity.8 These mice are more susceptible to both pre-
neoplasia and lung tumor formation after NNK exposure.5,8 
The preneoplastic lesions that develop are associated with 
the lung parenchyma and contain closely packed epithelial 
cells with reduced nuclear to cytoplasmic ratio and papillary 
growth, resembling adenomatous hyperplasia.8 To determine 
whether the COX-2 protein is a relevant target during the 
process of lung tumor development following NNK expo-
sure in HGF TG mice, we examined lungs of these animals 
with and without NNK treatment before the onset of lung 
tumors. At 10 weeks after treatment, aged-matched HGF TG 
lungs exposed to placebo show no evidence of preneoplasia 
either near airways or in the peripheral lung and little detect-
able COX-2 expression by immunohistochemistry(Fig. 2A). 
However, lungs of HGF TG mice 10 weeks after NNK treat-
ment show distinct highly positive COX-2 protein expres-
sion by immunohistochemistry (IHC), which was localized 
in and around preneoplastic areas (Fig. 2B, black arrow and 
high magnification inset). The epithelial cells within these 
areas demonstrate COX-2 positivity, and highly elevated 
COX-2 protein is also observed in infiltrating leukocytes 
(red arrows). This suggests that elevated COX-2 expression 
is part of a host response in the microenvironment of preneo-
plasias. In contrast, although COX-2 expression was induced 
in preneoplastic areas by NNK treatment in wild-type 
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littermates, the extent of induction and the infiltration by 
leukocytes was much lower compared with HGF TG animals 
(Fig. 2C and D). The infiltrating leukocytes seem to be a 
mixture of lymphocytes, macrophages, and neutrophils. In 
addition, inflammatory cells in bronchoalveolar lavage fluid 
showed a 2.5- and 4-fold increase in the number of macro-
phages and neutrophils, respectively, in fluid of HGF TG 
mice compared with wild-type mice (Supplemental Table 1, 
FIGURE 1.  Proliferation and invasion with single and combination treatments of celecoxib and crizotinib. A, 201T and 
273T lung cancer cells were treated with celecoxib or crizotinib alone or in combination using the concentrations that 
inhibit 50% (IC50) of each drug for 72 hours. Relative cell proliferation was determined with each treatment. Control was set 
to 100. The results show significant differences between the combination treatment and each single agent and the control. 
Maximum decreases were observed with combination treatment. Similar results were obtained with the IC50 and IC25 condi-
tions. ***p < 0.001, analysis of variance (ANOVA). B, 201T and 273T lung cancer cells were plated on Matrigel invasion 
chambers and were treated with celecoxib or crizotinib alone or in combination using the IC50 concentrations of each drug 
for 24 hours. Cells were fixed, stained, and counted for the number of invading cells. The combination treatment maximally 
inhibited cellular invasion in both cell lines. *p < 0.05; **p < 0.005; ***p < 0.001, ANOVA. n.s., Nonsignificant.
FIGURE 2.  Representative cyclo-
oxygenase-2 (COX-2) staining in 
lungs of hepatocyte growth factor 
transgenic (HGF TG) mice with and 
without NNK treatment. A, Control 
aged-matched lungs from HGF TG 
animals and (C) wild-type animals 
with no NNK treatment. B, HGF TG 
and (D) wild-type mouse lungs after 
animals were treated with 6-mg 
NNK and preneoplastic lesions were 
allowed to form for 10 weeks. These 
lesions are analogous to human atypi-
cal adenomatous hyperplasia. Lungs 
were formalin inflated and stained 
for COX-2 by immunohistochemistry. 
Representative images are shown. 
Red arrows represent COX-2-positive 
infiltrating leukocytes. Black arrows 
represent area of high-powered 
magnification.
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Supplemental Digital Content 2, http://links.lww.com/JTO/
A614). This observation shows that increased COX-2 expres-
sion is one of the selective changes occurring in the lungs of 
HGF TG mice following tobacco carcinogen exposure and 
validates the HGF TG mouse as a model to test dual therapy.
Combination Treatment with 
Crizotinib and Celecoxib Reduces Lung 
Tumorigenesis in Response to the Tobacco 
Carcinogen NNK in HGF TG Mice
Combination treatment was then compared in the pre-
vention of lung tumorigenesis experiment in which HGF 
TG mice were exposed to 24-mg total NNK over a period 
of 4 weeks and were treated with placebo, celecoxib alone, 
crizotinib alone, or the combination. Crizotinib (40 mg/kg), 
celecoxib (50 mg/kg), combined crizotinib and celecoxib, 
or placebo control was administered by oral gavage daily 
from week 3 until week 15, at which time lung tumors were 
evaluated. Concentrations were based on previous published 
studies in NSCLC xenografts. Table 1 shows the group sizes, 
mean number of tumors per animal, the range of tumors per 
animal, and mean and range of lung tumor size for each treat-
ment group. Group sizes were increased for single and dual 
treatments because of anticipated low tumor yields that would 
make it difficult to subsequently evaluate tumor biomarkers. 
Both number of tumors per animal and range of tumor num-
bers were lower with single treatment compared with control 
and were lowest with combination treatment. A highly signif-
icant decrease in the number of lung tumors per animal was 
observed with crizotinib treatment (mean 3.6, range 2–6), 
celecoxib treatment (mean 4.3, range 3–6), and combination 
treatment (mean 1.5, range 0–3) compared with placebo con-
trol (mean 9.9, range 6–13; p < 0.001, Poisson regression). 
Celecoxib alone reduced lung tumor numbers by 57% (Fig. 3A), 
whereas crizotinib reduced tumor numbers by 64%, and com-
bination treatment reduced the number of tumors per mouse 
by 85%. The number of tumors in the combination treatment 
group was also significantly lower than either single agent 
treatment (p < 0.001). Statistical assessment for synergy 
was negative based on exponential parameter estimates, and 
the effect of combination therapy was shown to be additive. 
Hyperplastic lesions were also present at this time point even 
when adenomas were present. We histologically examined 
the H&E-stained lung sections for the number of hyperplas-
tic lesions by treatment group. The combination treatment 
resulted in significantly fewer hyperplasia areas per lung 
(mean = 2.4; median = 2.0) compared with control (mean = 
4.1; median = 4.0, p < 0.001). Each single agent treatment 
group had decreased lesions with trends toward significance.
Lung tumors were also smaller in all treatment groups 
compared with control, and the range of tumor sizes was also 
smaller with treatments. As seen in Figure 3B, a significant 
decrease in mean tumor size was observed with crizotinib 
(mean 0.20 mm2), celecoxib (mean 0.22 mm2), and com-
bination (mean 0.15 mm2) compared with placebo (mean 
0.38 mm2, p < 0.001, mixed effects modeling). Size of tumors 
with crizotinib treatment was more variable but was still sig-
nificantly smaller than the control group. With combination 
treatment, the mean size of tumors (0.06 mm2) was also sig-
nificantly smaller than celecoxib alone (0.10 mm2) but did not 
reach significance compared with the mean size of crizotinib 
alone group (0.17 mm2), most likely due to the large variation 
observed with crizotinib alone.
Biomarkers of Prevention Effect
Biomarkers that may be modulated along with therapeu-
tic effect of single or combination treatments were examined 
by immunohistochemisty in lung tumors that were present 
at the time of euthanization. Biomarkers in the c-Met and 
COX-2 signaling pathways examined included P-AKT, P-P38, 
P-c-Met, P-STAT3, COX-2, PGE2, and P-MAPK. Several of 
these proteins were previously shown to be modulated by 
combining celecoxib with the EGFR inhibitor erlotinib in 
head and neck cancer models.22 Four biomarkers (P-c-Met, 
COX-2, PGE2, and P-MAPK) were optimally downmodu-
lated by combination treatment compared with single treat-
ment (Fig. 4). P-c-Met was detected in control tumors, with 
a mean staining score of 3. The mean score was reduced to 2 
in celecoxib treated tumors and 1 in crizotinib-treated tumors, 
demonstrating that inhibiting either COX-2 or c-Met reduced 
phosphorylation of c-Met. P-c-Met expression in combina-
tion-treated tumors was barely detectable (mean score 0.5), 
demonstrating that inhibiting both drug targets resulted in 
optimal suppression of c-Met phosphorylation. Level of 
PGE2 in lung tumors was high (mean IHC score of 4) in 
both control and crizotinib-treated tumors, while mean PGE2 
IHC score was reduced to 3 by celecoxib treatment and to an 
average of 1 by the combination. Similarly, the mean COX-2 
IHC score was 3 in control and crizotinib-treated tumors 
and was reduced to 2 by celecoxib. Combination treatment 
TABLE 1.  Results of NNK Exposure in HGF TG Mice
Control Celecoxib Crizotinib Combo
Number of animals 10 13 16 21
Total number of tumors 92 54 53 24
Mean no. of tumors per animal 9.98 4.33 3.60 1.50
No. of tumors per animal (min, max) (6, 13) (3, 6) (2, 6) (0, 3)
Mean tumor size (mm2) 0.38 0.22 0.20 0.15
Tumor size SD 0.37 0.10 0.17 0.06
Tumor size (min, max) (0.10, 2.24) (0.07, 0.69) (0.03, 1.25) (0.07, 0.29)
HGF TG, hepatocyte growth factor transgenic; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
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reduced this score further to a mean of 1. COX-2 staining was 
observed in both the malignant and the stromal compartments. 
Mean P-MAPK IHC score was reduced from 4 in controls to 3 
with treatment with crizotinib or celecoxib alone and reduced 
further to 2 with combination treatment. P-AKT, P-P38, and 
P-STAT3 showed little or no modulation with treatment (data 
not shown), suggesting that P-MAPK is the main signaling 
molecule downstream of c-Met and PGE2 that is affected by 
dual treatment consistent with the observed maximum down-
regulation of P-c-Met, COX-2, and P-MAPK by combination 
treatment in the cell lines used for the proliferation and inva-
sion studies (Supplemental Figure 2, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A615).
Because induction of EMT is an important downstream 
effect of COX-2 activation in lung cancer that contributes 
to invasion and metastasis,13 we examined the EMT marker 
E-cadherin, which is important in maintaining intercellular 
adhesion. We also examined two transcription factors that 
regulate E-cadherin: snail13 and Zeb-1.19 E-cadherin and snail 
were both found to be modulated by both single and dual 
treatment when compared with control: E-cadherin expres-
sion was significantly up-regulated 3.3-fold (p < 0.001) after 
treatment with celecoxib, 4-fold (p < 0.001) after crizotinib, 
and 4.2-fold after combination treatment (p < 0.001). The 
E-cadherin repressor, snail, was down-regulated 30% by both 
celecoxib and crizotinib (p < 0.001) and was down-regulated 
FIGURE 3. A, Boxplot of the number of tumors per mouse by treatment group analyzed by Poisson regression analysis. B, 
Boxplot of the log (tumor size mm2) by treatment group. A mixed effects model was used for analysis of tumor size. Horizontal 
line in box of boxplots represents the median. +, the mean; ; ns, nonsignificant. **p < 0.001; *p < 0.01.
FIGURE 4.  Biomarkers modulated by treat-
ment. P-c-Met, prostaglandin E2 (PGE2), 
cyclooxygenase-2 (COX-2), and P-MAPK 
expression was examined by immunohis-
tochemistry in tumors arising from differ-
ent treatment groups. Lungs were fixed in 
10% buffered formalin. Lung samples were 
paraffin embedded, sliced, and mounted 
on slides. Representative staining for each 
marker and treatment group is shown. 
Quantitation was performed from three to 
five tumors per treatment group on a 1 to 4 
scaling system, and determining the mean 
score. 1 = 1–25% positivity, 2 = 26–50% 
positivity, 3 = 51–75% positivity, and 4 
76–100% positivity. Scale bar= 100 μm.
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46% by dual treatment (p < 0.001) (Fig. 5A and B). Although 
E-cadherin expression was the highest and snail expression 
was lowest with combination treatment, expression of these 
markers in the combination treatment was not statistically dif-
ferent from single agent treatments. In this model, Zeb-1 was 
not found to be modulated by either single or dual treatment.
DISCUSSION
The use of combination therapies offers the advantage 
of dual inhibition of molecules with protumor effects. Dual 
inhibition may allow for greater antiproliferative effects and 
reduce or delay the emergence of resistance. Knowledge of 
how the two targets of interest interact may help identify good 
candidates for combination and define the patient population 
most likely to respond. The mechanistic rationale for this study 
was based on our prior published data in NSCLC cell lines 
that COX-2 was an important downstream signaling molecule 
of the c-Met receptor tyrosine kinase.9 We often observed 
COX-2 induction in NSCLC in response to HGF, and exami-
nation of downstream events showed that PGE2 produced by 
COX-2 triggered activation of the EGFR pathway, leading to 
long-term activation of c-Met through EGFR lateral signaling 
that was independent of HGF.8 We found that this lateral path-
way was very important for maximal induction of invasion.16 
Thus, c-Met and COX-2 participate in a signaling network 
that leads to reinforcing signaling of both EGFR and c-Met 
itself.8,16 In the current study, as predicted by our published 
model, we showed that dual inhibition of c-Met with the small 
molecule TKI crizotinib and of COX-2 with the selective 
COX-2 inhibitor celecoxib resulted in significantly less pro-
liferation and invasion in NSCLC cells in culture compared 
with single treatment. These increased effects were additive 
in nature. Although blocking HGF with a neutralizing anti-
body has also been successful as part of a dual inhibitor strat-
egy,5,8 a c-Met TKI has the advantage of additionally blocking 
HGF-independent signaling of c-Met caused by lateral sig-
naling from other tyrosine kinases.8,16,23 Although crizotinib 
can also target ALK in NSCLC with ALK rearrangements, 
ALK rearrangement is not present in the lung cancer cells or 
mouse model used in these experiments. The concentration of 
crizotinib necessary to observe effects on cell proliferation in 
vitro was higher than the reported IC
50
 for inhibiting c-Met 
phosphorylation. One factor that may account for this obser-
vation is that NSCLC release ligands for EGFR, and we have 
previously documented that EGFR signaling can substitute 
for c-Met signaling when c-Met is inhibited, making NSCLC 
cells more resistant to c-Met inhibition. In addition, Ron and 
Tie inhibition could be involved in the effect of crizotinib.
To validate use of dual therapy in an in vivo model, we 
used an HGF TG mouse that expresses human HGF under the 
control of the CCSP promoter. This model is preferential to a 
human tumor xenograft model because HGF is a paracrine fac-
tor that is produced almost exclusively by stromal cells in lung 
tumors, and murine HGF produced by the stroma of human 
tumor xenografts is not well recognized by human c-Met, 
whereas human HGF is able to activate murine c-Met. The 
HGF TG mouse exhibits increased local HGF production in 
the lungs and increased susceptibility to both preneoplasia and 
lung cancer after carcinogen exposure.8 Our prior observations 
showed that circulating HGF and the EGFR ligand amphi-
regulin are often elevated in patients with lung cancer com-
pared with smokers without lung cancer.5 In addition, the role 
of c-Met and EGFR lateral signaling suggests that EGFR can 
substitute for c-Met signaling and vice versa.16 Many NSCLCs 
with wild-type EGFR are driven by both EGFR and HGF.
In this study, we also showed that the target of cele-
coxib, COX-2, was highly expressed in the lungs of HGF TG 
mice within 10 weeks after exposure to the carcinogen NNK, 
and COX-2 expression was localized to preneoplasias that 
arose from NNK treatment. Some COX-2 protein localized 
to the lung epithelia itself in these preneoplastic lesions, but 
most of it was found localized to inflammatory cells infiltrat-
ing these lesions. Inhibition of COX-2 expressed in infiltrating 
FIGURE 5.  EMT was modulated by single and dual treat-
ment. Expression of E-cadherin and Snail was examined using 
immunohistochemistry in tumors arising from different treat-
ment groups. Representative staining for each marker and 
treatment group is shown. Quantitation was performed from 
three to five high-powered tumor fields per area by counting 
the number of positive cells per field. ***p < 0.001; *p < 0.05. 
Scale bar = 50 μm.
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inflammatory cells should prevent release of PGE2, which is 
known to stimulate protumor processes such as release of 
EGFR ligands and cytokines by tumor cells. By short circu-
iting COX-2, celecoxib could prevent reinforcing protumor 
interactions in the tumor microenvironment. Inflammation 
is expected in response to NNK, but because T cells, macro-
phages, and neutrophils express c-Met,24 HGF present in the 
airways of TG mice may also drive infiltration of leukocytes. 
HGF is a known inflammatory molecule,25 and COX-2 induc-
tion in response to HGF is part of that inflammatory process.10 
Furthermore, tumor-associated macrophages derived from 
primary lung tumors express high levels of both COX-2 and 
HGF.26 High HGF in the pulmonary environment is accom-
panied by the presence of pulmonary COX-2 in the context 
of tobacco carcinogen exposure, suggesting that COX-2 is a 
rational target for combination with a c-Met inhibitor. Our 
observations are consistent with the literature showing that 
pulmonary inflammation is an important lung cancer risk fac-
tor27 and is often observed in smokers with chronic obstruc-
tive pulmonary disease who are at increased lung cancer 
risk.28 Moreover, serum or tissue HGF levels are high in many 
inflammatory diseases.29,30
The combination of celecoxib and crizotinib yielded an 
additive inhibitory effect on lung tumor formation in which 
the resulting tumors were also smaller, and phosphorylation 
of c-Met was optimally reduced compared with celecoxib or 
crizotinib alone. In addition, the resulting tumors displayed 
optimal reduction of both COX-2 and PGE2 compared with 
single treatment. This suggests that both the induction of 
COX-2 that occurs through c-Met phosphorylation and the 
production of PGE2 by COX-2 were blunted by combination 
treatment. In contrast, single treatments resulted in a lesser 
degree of inhibition of these two targets by their respective 
inhibitors. The extent of activation of MAPK was also maxi-
mally reduced by the combination of celecoxib and crizotinib 
compared with single treatment, suggesting that the c-Met 
and PGE2 downstream signaling networks were disrupted. 
Because the process of EMT has a strong effect on the inva-
sive and progressive nature of lung cancer, we also examined 
EMT markers in lung tumors that arose, despite single or dual 
treatment. E-cadherin, which plays an important role in the 
maintenance of adherent junctions and which acts to inhibit 
tumor metastasis,31 was induced by both crizotinib and cele-
coxib and was also highly induced by combination treatment. 
Snail, a transcription factor that suppresses E-cadherin,31 was 
reduced by both crizotinib and celecoxib and was further 
reduced by combination treatment. Reduction in the EMT 
phenotype may be a biomarker of response to c-Met and 
COX-2 inhibitors, alone or in combination. Changes in PGE2 
might also be informative. An mRNA signature for NSCLC 
that consists of genes sorting with low E-cadherin and high 
snail expression, among other genes including several regu-
lated by HGF, was published recently.31 This gene signature 
or other markers of EMT might also be valuable in classify-
ing patients with an EMT phenotype who would respond to a 
c-Met/COX-2 combination targeted strategy or in evaluating 
the extent of response to such a combination. Recently, several 
mesenchymal markers including E-cadherin in combination 
with c-Met expression have been shown to be surrogate mark-
ers of response to c-Met inhibitors in patients with SCLC.32
We have previously shown that the HGF transgene in 
this mouse strain produces both KRAS mutant and wild-type 
tumors with a KRAS mutant frequency of approximately 40%.5 
We analyzed a subset of lung tumors from this experiment for 
KRAS mutation. Although we did observe a slight decrease in 
the KRAS mutation frequency rate with crizotinib treatment, 
but not with celecoxib treatment, this was not statistically sig-
nificant. It has been shown recently that KRAS mutation is a 
mechanism of crizotinib resistance,33 and it has been suggested 
that KRAS mutations may exist in separate subclonal popula-
tions that lack ALK gene rearrangement and that resistance is 
the result of emergence of a second driver oncogenic driver. 
Whether this combination treatment would be beneficial in 
KRAS mutant tumors requires further exploration.
These results show that in a pulmonary environment 
with heightened HGF/c-Met pathway activity that models what 
is observed in many lung cancer patients, dual inhibition of the 
c-Met and COX-2 pathways may enhance antitumor effects. 
Such a combination has the potential clinical benefit for lung 
cancer patients with dysregulated c-Met/COX-2 pathways, 
especially those that show evidence of an EMT phenotype. In 
this animal model, experimental treatment was administered 
concurrently with the tobacco carcinogen and represents a pre-
vention rather than a therapeutic setting. Whether these same 
responses would be observed in the setting of previously estab-
lished advanced lesions is not known. Future studies should 
test this combination in an animal model after lung adenocar-
cinomas are formed. Because COX-2 is induced downstream 
of other oncogenic drivers such as EGFR, combining COX-2 
inhibition with targeted therapies based on specific molecular 
aberrations may be a general strategy for increasing efficacy 
in cancer. The combination of EGFR inhibitors with celecoxib 
has been examined in several clinical trials. This combination 
showed efficacy in head and neck cancer,34,35 and downmodu-
lation of EGFR pathway markers correlated with response 
to combined treatment. In NSCLC, several trials have exam-
ined gefitinib or erlotinib in combination with celecoxib.36,37 
Although an increased response to the combination was not 
observed in unselected patients, both high tumor COX-2 
expression38 and reduction in circulating markers of EMT39 
have emerged as potential biomarkers of combination efficacy. 
Our results suggest that patients with tumor dysregulation of 
the HGF/c-Met pathway, perhaps in consort with evidence of 
COX-2 activity and/or EMT phenotype, might benefit from 
dual inhibition of the c-Met and COX-2 pathways. Clinical 
testing of such inhibitors in combination for lung cancer treat-
ment or prevention is warranted.
ACKNOWLEDGMENTS
The authors thank Beatriz Kanterewicz for technical 
assistance with Western blotting and cell culture.
REFERENCES
 1. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung can-
cer: correlation with clinical response to gefitinib therapy. Science 
2004;304:1497–1500.
1293Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 9, September 2014 Dual c-Met and COX-2 Inhibition of Lung Tumorigenesis
 2. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib 
(PF02341066), a dual mesenchymal-epithelial transition (MET) and ana-
plastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer 
patient with de novo MET amplification. J Thorac Oncol 2011;6:942–946.
 3. Goldman JW, Laux I, Chai F, et al. Phase 1 dose-escalation trial evalu-
ating the combination of the selective MET (mesenchymal-epithelial 
transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 
2012;118:5903–5911.
 4. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-
5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 
2011;11:1655–1662.
 5. Stabile LP, Rothstein ME, Keohavong P, et al. Targeting of both the c-Met 
and EGFR pathways results in additive inhibition of lung tumorigenesis 
in transgenic mice. Cancers (Basel) 2010;2:2153–2170.
 6. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating 
interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J 
Natl Cancer Inst 2011;103:1112–1122.
 7. Ujiie H, Tomida M, Akiyama H, et al. Serum hepatocyte growth factor 
and interleukin-6 are effective prognostic markers for non-small cell lung 
cancer. Anticancer Res 2012;32:3251–3258.
 8. Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM. 
Transgenic mice overexpressing hepatocyte growth factor in the air-
ways show increased susceptibility to lung cancer. Carcinogenesis 
2006;27:1547–1555.
 9. Siegfried JM, Gubish CT, Rothstein ME, Queiroz de Oliveira PE, Stabile 
LP. Signaling pathways involved in cyclooxygenase-2 induction by 
hepatocyte growth factor in non small-cell lung cancer. Mol Pharmacol 
2007;72:769–779.
 10. Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation pro-
motes carcinogenesis and epithelial-mesenchymal transition in hepato-
cellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 
2011;28:721–731.
 11. Lee YH, Suzuki YJ, Griffin AJ, Day RM. Hepatocyte growth factor regu-
lates cyclooxygenase-2 expression via beta-catenin, Akt, and p42/p44 
MAPK in human bronchial epithelial cells. Am J Physiol Lung Cell Mol 
Physiol 2008;294:L778–L786.
 12. Jones MK, Sasaki E, Halter F, et al. HGF triggers activation of the COX-2 
gene in rat gastric epithelial cells: action mediated through the ERK2 
signaling pathway. FASEB J 1999;13:2186–2194.
 13. Dohadwala M, Yang SC, Luo J, et al. Cyclooxygenase-2-dependent 
regulation of E-cadherin: prostaglandin E(2) induces transcriptional 
repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 
2006;66:5338–5345.
 14. Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer. Semin 
Oncol 2004;31(2 Suppl 7):45–52.
 15. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP. Cox-2 inactivates 
Smad signaling and enhances EMT stimulated by TGF-beta through a 
PGE2-dependent mechanisms. Carcinogenesis 2008;29:2227–2235.
 16. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-
independent potentiation of EGFR action by c-Met. Oncogene 
2011;30:3625–3635.
 17. Siegfried JM, Krishnamachary N, Gaither Davis A, Gubish C, Hunt JD, 
Shriver SP. Evidence for autocrine actions of neuromedin B and gastrin-
releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther 
1999;12:291–302.
 18. Okada T, Takigawa N, Kishino D, et al. Selective cyclooxygenase-2 
inhibitor prevents cisplatin-induced tumorigenesis in A/J mice. Acta Med 
Okayama 2012;66:245–251.
 19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the 
combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme 
Regul 1984;22:27–55.
 20. Siebzehnrubl FA, Silver DJ, Tugertimur B, et al. The ZEB1 pathway links 
glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 
2013;5:1196–1212.
 21. Lin X, Shang X, Manorek G, Howell SB. Regulation of the epithe-
lial-mesenchymal transition by claudin-3 and claudin-4. PLoS One 
2013;8:e67496.
 22. Fu S, Rivera M, Ko EC, et al. Combined inhibition of epidermal growth 
factor receptor and cyclooxygenase-2 as a novel approach to enhance 
radiotherapy. J Cell Sci Ther 2011;1:pii: S1–002.
 23. Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transac-
tivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in 
human hepatocellular carcinoma cells. J Cell Physiol 2006;207:261–270.
 24. Galimi F, Cottone E, Vigna E, et al. Hepatocyte growth factor is a regula-
tor of monocyte-macrophage function. J Immunol 2001;166:1241–1247.
 25. Kaibori M, Yanagida H, Nakanishi H, et al. Hepatocyte growth factor 
stimulates the induction of cytokine-induced neutrophil chemoattrac-
tant through the activation of NF-kappaB in rat hepatocytes. J Surg Res 
2006;130:88–93.
 26. Wang R, Zhang J, Chen S, et al. Tumor-associated macrophages provide 
a suitable microenvironment for non-small lung cancer invasion and pro-
gression. Lung Cancer 2011;74:188–196.
 27. Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: 
roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit 
Rev 2008;11:1–15.
 28. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, 
inflammation, and lung cancer. Proc Am Thorac Soc 2006;3:535–537.
 29. Nayeri F, Nilsson I, Hagberg L, et al. Hepatocyte growth factor levels in 
cerebrospinal fluid: a comparison between acute bacterial and nonbacte-
rial meningitis. J Infect Dis 2000;181:2092–2094.
 30. Kern MA, Bamborschke S, Nekic M, et al. Concentrations of hepatocyte 
growth factor in cerebrospinal fluid under normal and different pathologi-
cal conditions. Cytokine 2001;14:170–176.
 31. Byers LA, Diao L, Wang J, et al. An epithelial-mesenchymal transition 
gene signature predicts resistance to EGFR and PI3K inhibitors and iden-
tifies Axl as a therapeutic target for overcoming EGFR inhibitor resis-
tance. Clin Cancer Res 2013;19:279–290.
 32. Cañadas I, Rojo F, Taus Á, et al. Targeting epithelial-to-mesenchymal 
transition with Met inhibitors reverts chemoresistance in small cell lung 
cancer. Clin Cancer Res 2014;20:938–950.
 33. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to 
crizotinib in patients with ALK gene rearranged non-small cell lung can-
cer. Clin Cancer Res 2012;18:1472–1482.
 34. Shin DM, Zhang H, Saba NF, et al. Chemoprevention of head and neck 
cancer by simultaneous blocking of epidermal growth factor receptor and 
cyclooxygenase-2 signaling pathways: preclinical and clinical studies. 
Clin Cancer Res 2013;19:1244–1256.
 35. Saba NF, Hurwitz SJ, Kono SA, et al. Chemoprevention of head and neck 
cancer with celecoxib and erlotinib: results of a phase ib and pharmaco-
kinetic study. Cancer Prev Res (Phila) 2014;7:283–291.
 36. Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, 
Venkatramanamoorthy R, Wozniak A. Phase II study of gefitinib, an 
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), 
and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with 
platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol 
2007;2:299–305.
 37. Reckamp KL, Krysan K, Morrow JD, et al. A phase I trial to determine 
the optimal biological dose of celecoxib when combined with erlotinib 
in advanced non-small cell lung cancer. Clin Cancer Res 2006;12(11 Pt 
1):3381–3388.
 38. Fidler MJ, Argiris A, Patel JD, et al. The potential predictive value of 
cyclooxygenase-2 expression and increased risk of gastrointestinal hem-
orrhage in advanced non-small cell lung cancer patients treated with erlo-
tinib and celecoxib. Clin Cancer Res 2008;14:2088–2094.
 39. Reckamp KL, Gardner BK, Figlin RA, et al. Tumor response to combi-
nation celecoxib and erlotinib therapy in non-small cell lung cancer is 
associated with a low baseline matrix metalloproteinase-9 and a decline 
in serum-soluble E-cadherin. J Thorac Oncol 2008;3:117–124.
